Literature DB >> 9119996

Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma.

M J Kersten1, M R Klein, A M Holwerda, F Miedema, M H van Oers.   

Abstract

Although the high incidence of EBV-associated diffuse large cell lymphomas (DLCL) in HIV-1 infection is believed to be related to loss of immune control due to HIV-induced immune deficiency, it has been claimed that cytotoxic T lymphocyte (CTL) responses to EBV are longer lasting in HIV-1-infected persons than CTL directed against HIV-1 itself. We approached this apparent paradox by performing the first longitudinal study into the kinetics of EBV and HIV-specific CTL responses in HIV-infected patients progressing either to AIDS with non-Hodgkin's lymphoma (NHL) or AIDS with opportunistic infection (OI). Multiple samples were tested from HIV-1 seroconversion to AIDS-diagnosis. Four out of six patients that were either long-term asymptomatic or progressing to OI showed declining HIV-1 CTL precursor (CTLp) frequencies whereas EBV-CTLp remained stable, suggestive for HIV-1-specific immune exhaustion. In two patients rapidly progressing to AIDS-OI, a parallel decline of HIV-1- and EBV-CTL responses was seen, indicative for total collapse of cellular immunity. In all these six patients EBV-load remained low. However, in four out of five patients that progressed to DLCL, EBV-load was high and increasing several months preceding the NHL. In all five patients, EBV-CTLp decreased before the emergence of the NHL. Thus, our data show that in HIV-1 infection loss of HIV-1-specific T cell immunity is not necessarily paralleled by loss of EBV-specific T cell responses. The occurrence of AIDS-related DLCL is preceded by decreasing EBV-CTLp and increasing EBV load. Failing EBV-control might therefore be an important step in the pathogenesis of AIDS-related DLCL.

Entities:  

Mesh:

Year:  1997        PMID: 9119996      PMCID: PMC507972          DOI: 10.1172/JCI119315

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Human immunodeficiency virus type 1 (HIV-1)--and Epstein-Barr virus--specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1--infected persons.

Authors:  A M Geretti; M E Dings; C A van Els; C A van Baalen; F J Wijnholds; J C Borleffs; A D Osterhaus
Journal:  J Infect Dis       Date:  1996-07       Impact factor: 5.226

2.  HIV-1 core proteins expressed from recombinant vaccinia viruses.

Authors:  G Rautmann; M P Kieny; R Brandely; K Dott; M Girard; L Montagnier; J P Lecocq
Journal:  AIDS Res Hum Retroviruses       Date:  1989-04       Impact factor: 2.205

3.  Limiting dilution assays. Experimental design and statistical analysis.

Authors:  L W Strijbosch; W A Buurman; R J Does; P H Zinken; G Groenewegen
Journal:  J Immunol Methods       Date:  1987-02-26       Impact factor: 2.303

4.  Activation of HLA-restricted EBV-specific cytotoxic T cells does not require CD4+ (helper) T cells or exogenous cytokines.

Authors:  D M Fishwild; C J Benike; E G Engleman
Journal:  J Immunol       Date:  1988-03-15       Impact factor: 5.422

5.  Effects of human immunodeficiency virus on the cellular immune response to Epstein-Barr virus in homosexual men: characterization of the cytotoxic response and lymphokine production.

Authors:  R S Blumberg; T Paradis; R Byington; W Henle; M S Hirsch; R T Schooley
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

6.  Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers.

Authors:  Q Y Yao; P Ogan; M Rowe; M Wood; A B Rickinson
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

7.  Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men.

Authors:  P T Schellekens; M T Roos; F De Wolf; J M Lange; F Miedema
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

8.  AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization.

Authors:  S J Hamilton-Dutoit; G Pallesen; M B Franzmann; J Karkov; F Black; P Skinhøj; C Pedersen
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

Review 9.  Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency.

Authors:  J I Cohen
Journal:  Medicine (Baltimore)       Date:  1991-03       Impact factor: 1.889

10.  Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes.

Authors:  D A Thorley-Lawson; L Chess; J L Strominger
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307

View more
  19 in total

1.  Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.

Authors:  G S Ogg; S Kostense; M R Klein; S Jurriaans; D Hamann; A J McMichael; F Miedema
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 2.  Pathogenesis of AIDS-related lymphomas: molecular and histogenetic heterogeneity.

Authors:  G Gaidano; A Carbone; R Dalla-Favera
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

3.  Human immunodeficiency virus type 1- and cytomegalovirus-specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4(+) T cells.

Authors:  H M Spiegel; G S Ogg; E DeFalcon; M E Sheehy; S Monard; P A Haslett; G Gillespie; S M Donahoe; H Pollack; W Borkowsky; A J McMichael; D F Nixon
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Monitoring of epstein-barr virus DNA load in peripheral blood by quantitative competitive PCR.

Authors:  S J Stevens; M B Vervoort; A J van den Brule; P L Meenhorst; C J Meijer; J M Middeldorp
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

5.  Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy.

Authors:  M Dalod; M Dupuis; J C Deschemin; D Sicard; D Salmon; J F Delfraissy; A Venet; M Sinet; J G Guillet
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 6.  Management of AIDS-related non-Hodgkin's lymphomas.

Authors:  M J Kersten; R H Van Oers
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination.

Authors:  Paul F McKay; Dan H Barouch; Jörn E Schmitz; Ronald S Veazey; Darci A Gorgone; Michelle A Lifton; Kenneth C Williams; Norman L Letvin
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  High levels of human immunodeficiency virus infection of CD8 lymphocytes expressing CD4 in vivo.

Authors:  Alexandra Cochrane; Stuart Imlach; Clifford Leen; Gordon Scott; Dermot Kennedy; Peter Simmonds
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.

Authors:  P André; M Groettrup; P Klenerman; R de Giuli; B L Booth; V Cerundolo; M Bonneville; F Jotereau; R M Zinkernagel; V Lotteau
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  Contribution of HIV infection to mortality among cancer patients in Uganda.

Authors:  Anna E Coghill; Polly A Newcomb; Margaret M Madeleine; Barbra A Richardson; Innocent Mutyaba; Fred Okuku; Warren Phipps; Henry Wabinga; Jackson Orem; Corey Casper
Journal:  AIDS       Date:  2013-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.